A wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd. has granted an exclusive licence to a subsidiary of China Medical System Holdings Ltd. (CMS) to develop and commercialise seven generic products in mainland China. The collaboration with CMS now covers eight generic products including the seven products referred above. The total addressable market size for all these eight products is about $1 billion in mainland China.